Analysis of Vβ8.2 CDR3 sequences from spinal cord T cells of Lewis rats vaccinated or treated with TCR Vβ8.2-39-59 peptide

A. C. Buenafe, M. Vainiene, B. Celnik, Arthur Vandenbark, Halina Offner

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Experimental autoimmune encephalomyelitis (EAE) in the Lewis rat can be induced with the administration of Gp-BP. This disease appears to be mediated at least in part by Vβ8.2+ CD4+ T cells, which specifically recognize the BP72-89 encephalitogenic peptide. Treatment or protection with Vβ8.2 CDR2 39-59 peptide can suppress or prevent clinical signs of EAE, presumably through the activation of regulatory T cells. Interestingly, Vβ8.2+ T cells continue to persist in the spinal cord of protected animals, although their appearance in the central nervous system (CNS) is delayed when compared with control animals with EAE. As part of our effort to elucidate the mechanism(s) of peptide protection and therapy, we sought to determine whether the Vβ8.2+ T cells in the spinal cord of protected or treated rats were truly representative of those found in rats with clinical EAE. Therefore, we examined the following CNS samples for the Asp96Ser97 motif, which has been identified previously in Vβ8.2+ BP-specific, encephalitogenic T cell clones: 1) rats protected with Vβ8.2-39-59 peptide, 2) rats treated with Vβ8.2-39-59 peptide, and 3) control rats with EAE. Our findings indicate that EAE-associated Vβ8.2+ sequences can still be found in both peptide- treated and peptide-protected rats. It appears that administration of Vβ8.2 CDR2 peptide does not prevent EAE-associated Vβ8.2+ T cells from infiltrating the CNS and that other mechanisms are at work to prevent the development of EAE.

Original languageEnglish (US)
Pages (from-to)1556-1564
Number of pages9
JournalJournal of Immunology
Volume155
Issue number3
StatePublished - 1995

Fingerprint

Autoimmune Experimental Encephalomyelitis
Spinal Cord
T-Lymphocytes
Peptides
Central Nervous System
Regulatory T-Lymphocytes
Clone Cells

ASJC Scopus subject areas

  • Immunology

Cite this

Analysis of Vβ8.2 CDR3 sequences from spinal cord T cells of Lewis rats vaccinated or treated with TCR Vβ8.2-39-59 peptide. / Buenafe, A. C.; Vainiene, M.; Celnik, B.; Vandenbark, Arthur; Offner, Halina.

In: Journal of Immunology, Vol. 155, No. 3, 1995, p. 1556-1564.

Research output: Contribution to journalArticle

@article{bafdb4b823fd4327a1245759e3894b5f,
title = "Analysis of Vβ8.2 CDR3 sequences from spinal cord T cells of Lewis rats vaccinated or treated with TCR Vβ8.2-39-59 peptide",
abstract = "Experimental autoimmune encephalomyelitis (EAE) in the Lewis rat can be induced with the administration of Gp-BP. This disease appears to be mediated at least in part by Vβ8.2+ CD4+ T cells, which specifically recognize the BP72-89 encephalitogenic peptide. Treatment or protection with Vβ8.2 CDR2 39-59 peptide can suppress or prevent clinical signs of EAE, presumably through the activation of regulatory T cells. Interestingly, Vβ8.2+ T cells continue to persist in the spinal cord of protected animals, although their appearance in the central nervous system (CNS) is delayed when compared with control animals with EAE. As part of our effort to elucidate the mechanism(s) of peptide protection and therapy, we sought to determine whether the Vβ8.2+ T cells in the spinal cord of protected or treated rats were truly representative of those found in rats with clinical EAE. Therefore, we examined the following CNS samples for the Asp96Ser97 motif, which has been identified previously in Vβ8.2+ BP-specific, encephalitogenic T cell clones: 1) rats protected with Vβ8.2-39-59 peptide, 2) rats treated with Vβ8.2-39-59 peptide, and 3) control rats with EAE. Our findings indicate that EAE-associated Vβ8.2+ sequences can still be found in both peptide- treated and peptide-protected rats. It appears that administration of Vβ8.2 CDR2 peptide does not prevent EAE-associated Vβ8.2+ T cells from infiltrating the CNS and that other mechanisms are at work to prevent the development of EAE.",
author = "Buenafe, {A. C.} and M. Vainiene and B. Celnik and Arthur Vandenbark and Halina Offner",
year = "1995",
language = "English (US)",
volume = "155",
pages = "1556--1564",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "3",

}

TY - JOUR

T1 - Analysis of Vβ8.2 CDR3 sequences from spinal cord T cells of Lewis rats vaccinated or treated with TCR Vβ8.2-39-59 peptide

AU - Buenafe, A. C.

AU - Vainiene, M.

AU - Celnik, B.

AU - Vandenbark, Arthur

AU - Offner, Halina

PY - 1995

Y1 - 1995

N2 - Experimental autoimmune encephalomyelitis (EAE) in the Lewis rat can be induced with the administration of Gp-BP. This disease appears to be mediated at least in part by Vβ8.2+ CD4+ T cells, which specifically recognize the BP72-89 encephalitogenic peptide. Treatment or protection with Vβ8.2 CDR2 39-59 peptide can suppress or prevent clinical signs of EAE, presumably through the activation of regulatory T cells. Interestingly, Vβ8.2+ T cells continue to persist in the spinal cord of protected animals, although their appearance in the central nervous system (CNS) is delayed when compared with control animals with EAE. As part of our effort to elucidate the mechanism(s) of peptide protection and therapy, we sought to determine whether the Vβ8.2+ T cells in the spinal cord of protected or treated rats were truly representative of those found in rats with clinical EAE. Therefore, we examined the following CNS samples for the Asp96Ser97 motif, which has been identified previously in Vβ8.2+ BP-specific, encephalitogenic T cell clones: 1) rats protected with Vβ8.2-39-59 peptide, 2) rats treated with Vβ8.2-39-59 peptide, and 3) control rats with EAE. Our findings indicate that EAE-associated Vβ8.2+ sequences can still be found in both peptide- treated and peptide-protected rats. It appears that administration of Vβ8.2 CDR2 peptide does not prevent EAE-associated Vβ8.2+ T cells from infiltrating the CNS and that other mechanisms are at work to prevent the development of EAE.

AB - Experimental autoimmune encephalomyelitis (EAE) in the Lewis rat can be induced with the administration of Gp-BP. This disease appears to be mediated at least in part by Vβ8.2+ CD4+ T cells, which specifically recognize the BP72-89 encephalitogenic peptide. Treatment or protection with Vβ8.2 CDR2 39-59 peptide can suppress or prevent clinical signs of EAE, presumably through the activation of regulatory T cells. Interestingly, Vβ8.2+ T cells continue to persist in the spinal cord of protected animals, although their appearance in the central nervous system (CNS) is delayed when compared with control animals with EAE. As part of our effort to elucidate the mechanism(s) of peptide protection and therapy, we sought to determine whether the Vβ8.2+ T cells in the spinal cord of protected or treated rats were truly representative of those found in rats with clinical EAE. Therefore, we examined the following CNS samples for the Asp96Ser97 motif, which has been identified previously in Vβ8.2+ BP-specific, encephalitogenic T cell clones: 1) rats protected with Vβ8.2-39-59 peptide, 2) rats treated with Vβ8.2-39-59 peptide, and 3) control rats with EAE. Our findings indicate that EAE-associated Vβ8.2+ sequences can still be found in both peptide- treated and peptide-protected rats. It appears that administration of Vβ8.2 CDR2 peptide does not prevent EAE-associated Vβ8.2+ T cells from infiltrating the CNS and that other mechanisms are at work to prevent the development of EAE.

UR - http://www.scopus.com/inward/record.url?scp=0028984576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028984576&partnerID=8YFLogxK

M3 - Article

C2 - 7636217

AN - SCOPUS:0028984576

VL - 155

SP - 1556

EP - 1564

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 3

ER -